Details of the Drug | DrugMAP

General Information of Drug (ID: DM74JHW)

Drug Name

MK-4074

Indication

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Phase 1	[1]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C33H31N3O6
Canonical SMILES: CC1=CN(C2=C1C(=CC(=C2)C(=O)N3CCC4(CC3)CC(=O)C5=C(O4)C=CC(=C5)C6=CC(=CN=C6)C(=O)O)OC)C7CC7
InChI: 1S/C33H31N3O6/c1-19-18-36(24-4-5-24)26-13-21(14-29(41-2)30(19)26)31(38)35-9-7-33(8-10-35)15-27(37)25-12-20(3-6-28(25)42-33)22-11-23(32(39)40)17-34-16-22/h3,6,11-14,16-18,24H,4-5,7-10,15H2,1-2H3,(H,39,40)
InChIKey: WDBNGXLHMZSUEI-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 24964679
TTD ID: D04SOU

References

1	ClinicalTrials.gov (NCT01431521) Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008). U.S. National Institutes of Health.